DYN | Dyne Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	31.57 - 34.11
52 Week Range	6.40 - 47.45
Beta	1.26
Implied Volatility	85.83%
IV Rank	11.70%
Day's Volume	1,405,911
Average Volume	1,273,806
Shares Outstanding	100,401,000
Market Cap	3,316,245,030
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-09-17

Valuation
Profitability
Growth
Health
P/E Ratio	-9.23
Forward P/E Ratio	N/A
EPS	-3.58
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	143
Country	USA
Website	DYN

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

DYN's peers: ALXO, CDMO, CLDX, CORT, CYTK, DTIL, STOK, PLRX, RVMD, EWTX, CGEM, MLYS, DICE, KRTX, GRCL, THRX, GLUE, DSGN, ERAS, FOLD, GLYC, KALV, PRAX, PSTX, RCKT, RLMD, SNDX, SVRA, VCEL, XENE, XOMA

*Chart delayed

Analyzing fundamentals for DYN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see DYN Fundamentals page.

Watching at DYN technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on DYN Technicals page.